Background: Metabolic syndrome is characterized by a combination of central obesity, insulin resistance, dyslipidemia, and elevated blood pressure and may adversely affect reproductive and endocrine function. Objective: To determine the association of thyroid function, glycemic status, and lipid profile with menstrual disturbances in women with metabolic syndrome. Methodology: This analytical cross-sectional study was conducted at Department of Medicine Unit-4, Jinnah Hospital, Lahore from 1st July 2025 to 31st March 2026 included 189 women aged 18-45 years with metabolic syndrome attending a tertiary care hospital in Pakistan. Participants were recruited through non-probability consecutive sampling. Demographic and clinical characteristics and menstrual history were recorded. Thyroid function was assessed using serum thyroid-stimulating hormone and free T4, glycemic status using fasting plasma glucose and haemoglobin A1c, and lipid profile using total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Results: One hundred and twelve (59.3%) women had menstrual disturbances, while 77 (40.7%) had normal menstrual cycles. Irregular menstrual cycles were the most common abnormality, occurring in 44 (39.3%) affected women, followed by oligomenorrhea in 27 (24.1%). Women with menstrual disturbances had significantly higher thyroid-stimulating hormone (4.91±2.51 vs. 3.12±1.59 mIU/L), fasting plasma glucose (120.3±25.9 vs. 101.6±18.3 mg/dL), haemoglobin A1c (6.7±1.1% vs. 5.8±0.8%), total cholesterol (216.9±43.4 vs. 193.5±37.4 mg/dL), triglycerides (201.5±60.4 vs. 164.7±49.2 mg/dL), and low-density lipoprotein cholesterol (138.0±37.4 vs. 117.4±32.8 mg/dL), while free T4 and high-density lipoprotein cholesterol were significantly lower (all p<0.001). Conclusion: Menstrual disturbances were common among women with metabolic syndrome and were significantly associated with abnormalities in thyroid function, glycemic status, and lipid profile.
Metabolic syndrome is a group of interrelated metabolic abnormalities, typically associated with central obesity, insulin resistance or hyperglycemia, dyslipidaemia and raised blood pressure.1 It is now known to be an important health concern, especially in women of reproductive age, due to its links with type 2 diabetes mellitus, cardiovascular disease, endocrine dysfunction and reproductive disturbances.2 The hormonal and metabolic changes associated with metabolic syndrome can affect the function of the ovary, menstruation and fertility. The menstrual disturbance in such women may thus be a gynecological problem as well as a marker for any metabolic and endocrine abnormalities. The hypothalamic-pituitary-ovarian axis is responsible for the normal function of menstruation; several hormones and metabolic factors play a role in the regulation of the menstrual cycle. Any disruption in insulin sensitivity, thyroid, weight, or lipid levels can affect follicular development, ovulation and endometrial function.3 Women with metabolic syndrome may then experience irregular periods, oligomenorrhea, amenorrhea, prolonged menstruation, heavy or other cycle abnormalities in terms of duration or frequency. These disruptions can hurt reproduction and can also be linked with higher infertility rates and other chronic metabolic issues.4
Thyroid hormones play an important role in reproductive physiology and metabolic regulation. The changes in menstrual cyclicity in hypothyroidism and hyperthyroidism may be secondary to changes in gonadotropin secretion, sex hormone-binding globulin, prolactin, and ovarian function. Menstrual irregularity, anovulation, menorrhagia, and infertility have been linked to hypothyroidism, especially.5 Thyroid dysfunction can also result in alterations in weight gain, insulin resistance, and lipid metabolism, which can overlap with some of the components of metabolic syndrome. Thyroid function could be important in determining the cause and severity of menstrual disturbances in women with thyroid disorders, since these two disorders can occur together.6 Other factors that affect reproductive function are glycemic status. Insulin resistance plays a central role in the pathophysiology of metabolic syndrome and can result in a compensatory rise in insulin. Hyperinsulinemia may impact ovarian steroidogenesis and disrupt normal follicle development, leading to ovulatory dysfunction and irregular periods. Poorglycemic control can also create an imbalance of reproductive hormones and can be linked to obesity and chronic low-grade inflammation.7 Fasting plasma glucose and glycated hemoglobin values may thus be related to a metabolic disturbance that is important to menstrual function in women with metabolic syndrome.8
Also frequently found in metabolic syndrome are abnormalities in lipid metabolism, such as high cholesterol levels of the low-density type and low levels of the high-density type. Insulin resistance, central obesity, and systemic inflammation are closely related to dyslipidemia. While lipid abnormalities are viewed as cardiovascular risk factors, there is growing evidence that they can also be linked to reproductive and hormonal abnormalities.9 An altered lipid profile may be indicative of the overall metabolic pattern of the body that influences ovarian function and may be more common in women who have irregular or anovulatory cycles. The association between thyroid function, glycemic control, lipids, and menstrual disorders is complex due to the interaction.10 Insulin resistance and obesity can have an impact on endocrine function and menstruation, and thyroid dysfunction can impact lipid and glucose metabolism. Therefore, when considering any of these factors alone, it may not be sufficient to account for menstrual abnormalities in women with metabolic syndrome. This integrated evaluation of thyroid profile, glycemic status and lipid profile could help to understand the metabolic and endocrine disturbances associated with menstrual disturbances thoroughly.11,12
This analytical cross-sectional study was conducted at Department of Medicine Unit-4, Jinnah Hospital Lahore from 1st July 2025 to 31st March 2026 among 189 women with metabolic syndrome attending the outpatient departments of a tertiary care hospital in Pakistan. The study targeted all eligible women who presented during the study period and were enrolled sequentially until the desired sample size was reached. The study included women aged 18-45 years who had been diagnosed with metabolic syndrome, had spontaneous ovulations, and had given written informed consent. Women who were pregnant or lactating, and those with known polycystic ovary syndrome, hyperprolactinemia, premature ovarian insufficiency, structural uterine abnormalities or other known causes of menstrual disturbances were excluded. Other exclusion criteria included women who were taking hormonal contraceptives or hormone replacement therapy, as well as those who had severe conditions such as renal and hepatic disease and systemic illness. Participants who took medications with a well-established effect on thyroid
function, glucose metabolism or lipids were excluded.
Demographic and clinical data such as age, marital status, parity, body mass index (BMI), waist circumference, BP, duration of metabolic syndrome, medications and medical history were collected on a data collection sheet. Menstrual history was gathered using patient interviews. Each participant had a detailed menstrual history taken, such as cycle length, regularity of the cycle, the duration of the bleeding, blood flow, and history of amenorrhea. Irregular menstrual cycles, oligomenorrhea, amenorrhea, polymenorrhea and/or prolonged and heavy menstrual bleeding were considered menstrual disturbances. Based on pre-specified clinical parameters, the participants were divided into two groups: those who had normal menstruation and those who experienced menstrual disturbances. Overnight fasted samples of venous blood were obtained. Thyroid function was determined by serum TSH and free T4 levels. Fasting plasma glucose levels and glycated hemoglobin were used to determine glycemic status. The lipid profile was determined by measuring total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoproteins (LDL). Standardized laboratory procedures were used for all biochemical investigations carried out in the hospital laboratory. The main results were the relationship between thyroid function, glycemic status, and lipid profile and menstrual disorders in women suffering from metabolic syndrome. The individual relationships between thyroid-stimulating hormone, free thyroxine, fasting plasma glucose, HbA1c, triglycerides, HDL-C, LDL-C, and total cholesterol and menstrual disturbances were evaluated in secondary analyses.
The data were entered and analyzed through SPSS-26. For quantitative variables, age, BMI, TSH, FT4, FPG, HbA1c and lipoproteins, mean ± SD is reported when the variables were normally distributed, and median with interquartile range is reported when they were not normally distributed. The Shapiro-Wilk test was used to determine the normality of quantitative variables. Categorical variables were displayed as frequencies and percentages. The p value <0.05 was used as the cut-off for statistical significance.
The mean age was 32.6±7.1 years and the mean BMI was 31.4±4.8 kg/m². The mean waist circumference was 96.8±10.7 cm. Most participants were married, accounting for 151 (79.9%), while 54 (28.6%) were nulliparous and 92 (48.7%) had hypertension. Menstrual disturbances were reported in 112 (59.3%) women. The mean TSH level was 4.18±2.36 mIU/L and the mean free T4 level was 1.08±0.24 ng/dL. Mean fasting plasma glucose was 112.7±24.8 mg/dL and mean HbA1c was 6.3±1.1%. Regarding lipid profile, mean total cholesterol, triglycerides, LDL-C, and HDL-C were 207.4±42.6 mg/dL, 186.5±58.7 mg/dL, 129.6±36.9 mg/dL and 41.8±9.4 mg/dL respectively (Tables 1-2).
Among the 112 women with menstrual disturbances, irregular menstrual cycles were the most common pattern, observed in 44 (39.3%) participants. Oligomenorrhea was reported in 27 (24.1%), heavy or prolonged menstrual bleeding in 21 (18.8%), amenorrhea in 12 (10.7%), and polymenorrhea in 8 (7.1%) women (Table 3, Fig. 1).
Women with menstrual disturbances had significantly higher mean TSH levels (4.91±2.51 vs. 3.12±1.59 mIU/L), fasting plasma glucose (120.3±25.9 vs. 101.6±18.3 mg/dL), HbA1c (6.7±1.1% vs. 5.8±0.8%), total cholesterol (216.9±43.4 vs 193.5±37.4 mg/dL), triglycerides (201.5±60.4 vs 164.7±49.2 mg/dL), and LDL-C (138.0±37.4 vs. 117.4±32.8 mg/dL). In contrast, mean free T4 (1.02±0.22 vs. 1.17±0.23 ng/dL) and HDL-C (39.1±8.7 vs. 45.7±9.1 mg/dL) were significantly lower among women with menstrual disturbances. All these differences were statistically significant with p<0.001 (Table 4, Fig. 2).
Each 1 mIU/L increase in TSH was associated with a 31% increase in the odds of menstrual disturbance (aOR 1.31, 95% CI 1.12–1.54; p=0.001), while each 1% increase in HbA1c was associated with a 72% increase in the odds (aOR 1.72, 95% CI 1.21–2.45; p=0.003). Each 10 mg/dL increase in triglycerides was associated with an 8% increase in the odds of menstrual disturbance (aOR 1.08, 95% CI 1.02–1.14; p=0.009) [Table 5, Fig. 3].
Table 1: Demographic information of clinical and
biochemical characteristics (n = 189)
|
Variable |
No. |
% |
|
Married |
151 |
79.9 |
|
Nulliparous |
54 |
28.6 |
|
Hypertension |
92 |
48.7 |
|
Menstrual disturbance |
112 |
59.3 |
Table 2: Descriptive statistics of the participants (n=189)
|
Variable |
Mean±SD |
|
Age (years) |
32.6±7.1 |
|
BMI (kg/m²) |
31.4±4.8 |
|
Waist circumference (cm) |
96.8±10.7 |
|
TSH (mIU/L) |
4.18±2.36 |
|
Free T4 (ng/dL) |
1.08±0.24 |
|
Fasting plasma glucose (mg/dL) |
112.7±24.8 |
|
HbA1c (%) |
6.3±1.1 |
|
Total cholesterol (mg/dL) |
207.4±42.6 |
|
Triglycerides (mg/dL) |
186.5±58.7 |
|
LDL-C (mg/dL) |
129.6±36.9 |
|
HDL-C (mg/dL) |
41.8±9.4 |
Table 3: Pattern of menstrual disturbances among affected
women (n = 112)
|
Menstrual disturbance |
No. |
% |
|
Irregular menstrual cycles |
44 |
39.3 |
|
Oligomenorrhea |
27 |
24.1 |
|
Heavy/prolonged menstrual bleeding |
21 |
18.8 |
|
Amenorrhea |
12 |
10.7 |
|
Polymenorrhea |
8 |
7.1 |
Table 4: Comparison of biochemical parameters according to menstrual status
|
Variable |
Normal Menstruation (n=77) |
Menstrual Disturbance (n=112) |
p-value |
|
TSH (mIU/L) |
3.12±1.59 |
4.91±2.51 |
<0.001 |
|
Free T4 (ng/dL) |
1.17±0.23 |
1.02±0.22 |
<0.001 |
|
Fasting plasma glucose (mg/dL) |
101.6±18.3 |
120.3±25.9 |
<0.001 |
|
HbA1c (%) |
5.8±0.8 |
6.7±1.1 |
<0.001 |
|
Total cholesterol (mg/dL) |
193.5±37.4 |
216.9±43.4 |
<0.001 |
|
Triglycerides (mg/dL) |
164.7±49.2 |
201.5±60.4 |
<0.001 |
|
LDL-C (mg/dL) |
117.4±32.8 |
138.0±37.4 |
<0.001 |
|
HDL-C (mg/dL) |
45.7±9.1 |
39.1±8.7 |
<0.001 |
Table 5: Multivariable logistic regression analysis for factors associated with menstrual disturbances
|
Predictor |
Adjusted OR |
95% CI |
p-value |
|
TSH, per 1 mIU/L increase |
1.31 |
1.12–1.54 |
0.001 |
|
HbA1c, per 1% increase |
1.72 |
1.21–2.45 |
0.003 |
|
Triglycerides, per 10 mg/dL increase |
1.08 |
1.02–1.14 |
0.009 |
|
HDL-C, per 5 mg/dL increase |
0.79 |
0.65–0.96 |
0.018 |
|
BMI, per kg/m2 increase |
1.06 |
0.99–1.14 |
0.094 |
|
Age, per year increase |
1.02 |
0.97–1.07 |
0.437 |
|
Parity |
1.11 |
0.82–1.50 |
0.501 |
In the present study, the relationship of thyroid function, glucose metabolism and lipid profile with menstrual disturbances was assessed in women with metabolic syndrome. One hundred and one (53.4%) of the 189 patients had menstrual disturbances and 77 (40.7%) had normal menstruation. The most common abnormality was irregular menstrual cycles, followed by oligomenorrhea, heavy and long menstruation, amenorrhea and polymenorrhea. The women with menstrual disturbances had significantly elevated levels of TSH, fasting plasma glucose, HbA1c, total cholesterol, triglycerides and LDL-C and significantly lower free T4 and HDL-C levels than the women with normal menstruation. Higher TSH, HbA1c, and triglyceride levels were also found to be independently associated with menstrual disturbances, while higher HDL-C was associated with decreased odds of menstrual abnormalities, as shown by multivariable analysis. Menstrual disturbances in the present study were frequent and indicate a relationship between the reproductive disorders and metabolic abnormalities of metabolic syndrome.13 In a population-based study of 2742 Korean women, menstrual irregularity was significantly associated with metabolic syndrome even after adjustment for potential confounding factors. These findings are similar to the results of that study, where women with menstrual disturbances had higher odds of metabolic syndrome, higher waist circumference, higher triglycerides and lower HDL-C concentration. A prospective study of Tehran's reproductive-age women (n=2,128) further showed that menstrual cycle irregularity was related to later metabolic abnormalities, which added longitudinal evidence to support the close relationship between menstrual irregularity and metabolic health.14-16
Menstrual status was significantly related to thyroid function in the present study. Women with menstrual disturbances had a mean TSH of 4.91±2.51 mIU/L, which is significantly higher than the mean TSH of 3.12±1.59 mIU/L for women with normal menstruation, and free T4 levels were significantly lower. In addition, for each mIU/L rise in TSH, the odds of menstrual disturbance were increased by 31% after adjustment.17 Thyroid function is important in reproductive physiology, influencing ovarian function, sex hormone-binding globulin, gonadotropin levels, prolactin levels, and endometrial activity. Thus, any thyroid imbalance can have an impact on the length of the cycle, ovulation, and the amount of menstrual blood loss. From Pakistan, it can be concluded that thyroid disorders are clinically significant among females who have menstrual disorders. A cross-sectional study was done among women aged 40-55 years with abnormal uterine bleeding in Hayatabad Medical Complex, Peshawar and the results showed that the burden of subclinical hypothyroidism was significant with mean TSH level of 4.4±2.5 mIU/L.18
Women who had menstrual disturbances also had significantly poorer glycemic status. Women with menstrual disturbances had a mean fasting plasma glucose of 120.3±25.9 mg/dL versus 101.6±18.3 mg/dL in women with normal menstruation, and a mean HbA1c of 6.7±1.1% versus 5.8±0.8%, respectively. HbA1c was also independently related to menstrual disturbances after adjustment for other factors, with 72% higher adjusted odds of menstrual abnormality for every 1% increase in HbA1c. These results could be related to the influence of insulin resistance and chronic hyperglycemia on the reproductive axis. Hyperinsulinemia may affect ovarian steroidogenesis, follicular development and play a role in anovulation and menstrual cyclicity.19 Deterioration of glycemic status may then be associated with increased reproductive dysfunction since insulin resistance is at the heart of metabolic syndrome. The simultaneous assessment of thyroid, glycemic and lipid parameters was an important aspect of the present study. Often these abnormalities are intertwined and coexistent. Abnormal thyroid activity may have detrimental effects on lipid and glucose metabolism, and insulin resistance and obesity can have effects on reproductive endocrine function. The various metabolic and hormonal pathways may therefore be involved in menstrual abnormalities and be interrelated, and are not necessarily distinct disorders. The independent relationships of TSH, HbAc, triglycerides and HDL-C with menstrual disturbances indicate that these parameters may be the best way to assess the situation than measuring one parameter alone.20
The findings could also have clinical applications. When women have menstrual disturbances and metabolic syndrome, it should not be regarded as a gynecological disorder. Thyroid function, glycemic control and lipid status should be evaluated in females with irregular periods, oligomenorrhea, amenorrhea or abnormal menses, especially if they have metabolic syndrome. On the other hand, clinicians treating women with metabolic syndrome should take a comprehensive menopausal history as it may be a clue for underlying metabolic or endocrine abnormalities. However, although the present study was cross-sectional, early recognition and/or proper control of thyroid dysfunction, glycemic control, and dyslipidaemia might potentially lead to better overall metabolic and reproductive health, since the correction of these abnormalities does not directly lead to menstrual normalization. The results should be interpreted with some caution taking into account several limitations. Results of the cross-sectional design were unable to establish temporal or causal relationships between biochemical abnormalities and menstrual disturbances. The study was done at a single tertiary care center, which may restrict the applicability of the results to the general population. Menstrual patterns were also partly based on the participant's history and may thus have been influenced by recall bias. Other factors including dietary patterns, physical activity, psychological stress, socioeconomic status and reproductive hormones were not completely assessed. Women who were known to have polycystic ovary syndrome were excluded because of the potential for this to be an important source of confounding, but this would not necessarily affect the observed associations if the women were not diagnosed with it.
Women with metabolic syndrome also had menstrual disturbances, which were significantly associated with thyroid, glycemic, and lipid abnormalities. Women with menstrual disturbances showed higher TSH, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, and LDL-C levels and lower free T4 and HDL-C levels. Increased TSH and HbAc and triglycerides were independently associated with menstrual disturbances; increased HDL-C was independently associated with decreased odds of menstrual abnormalities. The results indicate that women with metabolic syndrome who have menstrual disorders should be evaluated for thyroid dysfunction, glycemic control, and lipid status to help identify and treat such metabolic and endocrine disorders at an early stage.